Corporate | 15 October 2008 14:01
ECKERT & ZIEGLER Strahlen- und Medizintechnik AG / Miscellaneous
Release of a Corporate News, transmitted by DGAP - a company of EquityStory
AG.
The issuer / publisher is solely responsible for the content of this announcement.
----------------------------------------------------------------------
Berlin, October 15, 2008. This year’s travel grants from Eckert & Ziegler
Strahlen- und Medizintechnik AG (ISIN DE 0005659700) have been awarded to
five nuclear medicine scientists from the USA, Japan, Sweden, Switzerland,
and Austria. The prize-winners were selected by a jury from the European
Association of Nuclear Medicine (EANM) from a total of 400 entries. Work in
the fields of cancer and dementia diagnostics received recognition. The
travel grants, which amount to 1,000 euros, were presented today on the
occasion of the 10th anniversary of the Berlin-based company Eckert &
Ziegler AG at the annual congress of the EANM in Munich to:
M. Samuraki, Ph.D., Toyama City Hospital, Japan: Prevalence of Reduced
Glucose Metabolism or Gray-Matter Concentration in Healthy Apo E ε 4
Carriers: The Ishikawa Brain Imaging Study
D. Putzer, Ph.D., Innsbruck Medical University, Austria: Correlation of
18F-FDG PET/CT and 68Ga-DOTA-TOC PET/CT with tissue markers of poor
prognosis in neuroendocrine tumor disease
A. Varrone, Ph.D., Karolinska Institutet, Sweden: Point Spread Function
Reconstruction of High-Resolution Research Tomograph - HRRT - PET-Images
Improves In Vivo Neuroreceptor Quantification
C.B. Hruska, Ph.D., Mayo Clinic, USA: Concordance of Molecular Breast
Imaging and Breast MRI findings: A retrospective review
T. Cazaentre, Ph.D., Hôpitaux Universitaires de Genève, Switzerland:
Predictive Factors for Response of Non Hodgkin Lymphomas (NHL) to
Radioimmunotherapy (RIT) derived from FDG PET
'In presenting the ’EANM Eckert & Ziegler Abstract Award’ we wish to
encourage young researchers to present their ideas to a wider audience and
to collaborate more in exchanging ideas with other researchers engaged in
the field of nuclear medicine. We hope that this will help to ensure that
the enormous progress which has been made in medical imaging can soon be
transformed into more precise, faster or cheaper methods of diagnosis and
therapy,' explained Dr. Andreas Eckert, CEO of Eckert & Ziegler.
Eckert & Ziegler AG, which in 2008 will achieve sales of roughly 70 million
euros with approx. 450 employees, is one of the world’s largest providers
of isotope component technology for radiation therapy and nuclear medicine.
You can find further information about the Eckert & Ziegler travel grant at
www.eanm.org.
The Board of Directors
Your point of contact if you have any further questions:
Eckert & Ziegler AG
Karolin Riehle, Investor Relations & PR, Robert-Rössle-Str. 10, 13125
Berlin, Germany
Tel.: +49 (0) 30 / 941084-138, Fax-112, E-mail: karolin.riehle@ezag.de,
www.ezag.de
15.10.2008 Financial News transmitted by DGAP
----------------------------------------------------------------------
Language: English
Issuer: ECKERT & ZIEGLER Strahlen- und Medizintechnik AG
Robert-Rössle-Str. 10
13125 Berlin
Deutschland
Phone: +49 (0)30 941 084-0
Fax: +49 (0)30 941 084-112
E-mail: thomas.scheuch@ezag.de
Internet: www.ezag.de
ISIN: DE0005659700
WKN: 565970
Listed: Regulierter Markt in Frankfurt (Prime Standard), Stuttgart;
Freiverkehr in Berlin, München, Hamburg, Düsseldorf
End of News DGAP News-Service
---------------------------------------------------------------------------